Therapy: What evidence should guide the use of thiazolidinediones?

Nature Reviews Endocrinology

Volumn 6, Issue 11, 2010, Pages 600-602

  Riddle, Matthew C ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE;

BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GLYCEMIC CONTROL; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; LIVER INJURY; MAJOR CLINICAL STUDY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SHORT SURVEY; SYSTEMATIC REVIEW;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THIAZOLIDINEDIONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77958597752     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2010.156     Document Type: Short Survey

References (10)

1. Yki-Järvinen, H. Thiazolidinediones. N. Engl. J. Med. 351, 1106-1118 (2004).
2. singh, s., Loke, Y. K. & Furberg, C. D. Thiazolidinediones and heart failure. A teleoanalysis. Diabetes Care 30, 2148-2153 (2007).
3. Loke, Y. K., singh, s. & Furberg, C. D. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 180, 32-39 (2009).
4. nissen, s. e. & wolski, K. Rosiglitazone revisited. An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 170, 1191-1201 (2010).
5. Mannucci, e. et al. Cardiac safety profile of rosiglitazone. A comprehensive meta-analysis of randomized clinical trials. Int. J. Cardiol. doi:10.1016/j.ijcard.2009.01.064.
6. Graham, D. J. et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA 304, 411-418 (2010).
7. Home, P. D. et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (ReCORD): a multicentre, randomized, open-label trial. Lancet 373, 2125-2135 (2010).
8. The BARi 2D study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N. Engl. J. Med. 360, 2503-2515 (2009).
9. writing group for the women's Health initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's Health initiative randomized controlled trial. JAMA 288, 321-333 (2002).
10. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipidlowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288, 2981-2997 (2002).